Driving Digital Transformation in Pharma: Microinnova’s Role in the TWIN4PHARMA Initiative

Microinnova is working on the digitalization towards tomorrow’s process technology, especially for pharma applications. A very important activity for this objective is the TWIN4PHARMA initiative, led by the Research Center Pharmaceutical Engineering (RCPE), where the review of the 1^st year has been completed successfully. The COMET Module focused on driving the digital and sustainable transformation of pharmaceutical process development.

Key aspects for Microinnova include:

• Technology Focus: Integrating advanced digital technologies, such as AI-driven modeling and predictive analytics, to optimize development processes.
• Core Approach: Utilizing computer-aided process optimization for small molecules. This includes advanced simulations and predictive modeling for flow chemistry, purification, and crystallization.
• Outcomes/Impact: The expected results are a more viable and sustainable pharmaceutical production in Europe, leading to:
  • Reduced costs.
  • Shortened development timelines.
  • Enhanced scalability, stability, and efficiency in manufacturing.

Microinnova’s engagement in the TWIN4PHARMA initiative demonstrates its strong commitment to advancing digitalization and sustainability in pharmaceutical process technology. By integrating AI-driven modeling, predictive analytics, and computer-aided optimization, the company is helping to shape a more efficient, cost-effective, and environmentally responsible future for pharmaceutical manufacturing in Europe.